On May 12, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) revived the Regents of the University of California’s (Regents) challenge to the Broad Institute’s CRISPR-Cas9 patents, overturning a 2022 decision by...more
7/3/2025
/ Appeals ,
Biotechnology ,
CAFC ,
CRISPR ,
Life Sciences ,
Patent Litigation ,
Patent Ownership ,
Patent Trial and Appeal Board ,
Patents ,
Popular ,
Remand
We previously reported a decision by the U.S. Food and Drug Administration (FDA), denying the premarketing authorization of several flavored e-cigarette product. On April 2, 2025, the Supreme Court of the United States...more
On October 11, 2018, the USPTO published a Final Rule in the Federal Register, adopting a new standard for interpreting claims in trial proceedings before the patent trial and appeal board (PTAB)....more
11/1/2018
/ America Invents Act ,
Appeals ,
Broadest Reasonable Interpretation Standard ,
Claim Construction ,
Covered Business Method Proceedings ,
Final Rules ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Phillips Standard ,
Post-Grant Review ,
Prior Art ,
USPTO
On November 7, 2016, the U.S. Supreme Court declined to review an appeal from a Third Circuit decision finding that a settlement between GlaxoSmithKline (GSK) and Teva Pharmaceutical Industries Ltd. (Teva) involving the...more
11/15/2016
/ Anti-Competitive ,
Antitrust Violations ,
Appeals ,
Denial of Certiorari ,
FTC v Actavis ,
Generic Drugs ,
GlaxoSmithKline ,
No-AG Agreement ,
Pay-For-Delay ,
Popular ,
Product Exclusivity ,
Reverse Payment Settlement Agreements ,
Rule-of-Reason Analysis ,
SCOTUS ,
Solicitor General ,
Teva Pharmaceuticals